No profile data available.
Scynexis, Inc. (SCYX) is a healthcare company in the additional infection treatment pharmaceuticals industry, based in Jersey City, United States, with about 18 full-time employees.
It reported revenue of $20.60 million for fiscal year 2025, up 449.9% from fiscal year 2024, and net income of -$8.61 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $235,000, down 82.8% from a year before. Its market capitalization was $40.59 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Scynexis reported $20.60 million in revenue for fiscal year 2025, up 449.9% from $3.75 million in fiscal year 2024. In Q2 2026 revenue was $235,000.
$40.59 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional infection treatment pharmaceuticals) include Tarsus Pharmaceuticals, Inc. (TARS), Daré Bioscience, Inc. (DARE), Pulmatrix, Inc. (PULM), 60 Degrees Pharmaceuticals, Inc. (SXTP).